Financial Review: ABIVAX Société Anonyme (NASDAQ:ABVX) vs. SIGA Technologies (NASDAQ:SIGA)

SIGA Technologies (NASDAQ:SIGA) and ABIVAX Société Anonyme (NASDAQ:ABVX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Insider and Institutional Ownership

55.4% of SIGA Technologies shares are held by institutional investors. Comparatively, 47.9% of ABIVAX Société Anonyme shares are held by institutional investors. 1.5% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

SIGA Technologies has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, ABIVAX Société Anonyme has a beta of -0.2, indicating that its stock price is 120% less volatile than the S&P 500.

Valuation & Earnings

This table compares SIGA Technologies and ABIVAX Société Anonyme”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SIGA Technologies	$138.72 million	2.87	$68.07 million	$0.82	6.80
ABIVAX Société Anonyme	N/A	N/A	-$159.90 million	N/A	N/A

SIGA Technologies has higher revenue and earnings than ABIVAX Société Anonyme.

Profitability

This table compares SIGA Technologies and ABIVAX Société Anonyme’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SIGA Technologies	49.33%	49.06%	38.72%
ABIVAX Société Anonyme	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for SIGA Technologies and ABIVAX Société Anonyme, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SIGA Technologies	0	0	0	0	0.00
ABIVAX Société Anonyme	0	1	5	1	3.00

ABIVAX Société Anonyme has a consensus target price of $38.67, indicating a potential upside of 550.95%. Given ABIVAX Société Anonyme’s stronger consensus rating and higher probable upside, analysts plainly believe ABIVAX Société Anonyme is more favorable than SIGA Technologies.

Summary

SIGA Technologies beats ABIVAX Société Anonyme on 8 of the 12 factors compared between the two stocks.

About SIGA Technologies

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.